Actionable news
All posts from Actionable news

Aquinox Pharmaceuticals Announces Results From Phase 2 KINSHIP Trial With AQX-1125 in Patients With Atopic Dermatitis

VANCOUVER, British Columbia, Nov. 02, 2015 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today its Phase 2 KINSHIP clinical trial failed to demonstrate efficacy in patients with mild to moderate atopic dermatitis.

"We believe that KINSHIP was well conducted and the results do not warrant continued development for this indication," said David Main, President & CEO at Aquinox. "Given the results of our LEADERSHIP trial, our focus will continue to be on the further development of AQX-1125 in bladder pain syndrome/interstitial cystitis (BPS/IC). To this end, we are looking forward to our end-of-Phase 2 meeting with the United States Food and Drug Administration scheduled for December 8, 2015 to discuss pivotal trial designs.”

The KINSHIP trial was a multicenter, randomized, double-blind, placebo-controlled, Phase 2 clinical trial investigating the ability of AQX-1125 to reduce characteristic symptoms in 54 patients with mild to moderate atopic dermatitis. Patients treated with 200 mg oral, once daily AQX-1125, compared to placebo, did not meet the primary endpoint of improvement from baseline in Total Lesion Symptom Score after 12 weeks of treatment.

The KINSHIP trial demonstrated AQX-1125 to be well tolerated and adverse events were consistent with prior clinical trials. No serious adverse events were recorded during the trial.

About AQX-1125

AQX-1125, Aquinox's lead...